Cargando…

Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites

Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of...

Descripción completa

Detalles Bibliográficos
Autores principales: Pillai, Manon, Davies, Michelle M., Thistlethwaite, Fiona C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509731/
https://www.ncbi.nlm.nih.gov/pubmed/33015538
http://dx.doi.org/10.1177/2515135520944355
_version_ 1783585657258508288
author Pillai, Manon
Davies, Michelle M.
Thistlethwaite, Fiona C.
author_facet Pillai, Manon
Davies, Michelle M.
Thistlethwaite, Fiona C.
author_sort Pillai, Manon
collection PubMed
description Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of clinical development. The field has seen a rapid expansion of academic and commercial entities successfully translating ATMP research into the clinic. This is reflected in projection that the global gene and cell therapy market will be worth US $11.96 billion by 2025. However, these treatments are complex to deliver and frequently do not fit naturally into established healthcare systems. In the United Kingdom (UK) there has been a long-standing interest in ATMP research and, in order to meet the ambition to act as an international hub of activity for delivery of ATMPs, a collaborative network of Advanced Therapy Treatment Centres (ATTCs) has been established. This review explores the challenges of delivery in the clinical setting, focussing on one form of ATMP, Adoptive Cell Therapy (ACT). We describe the strategy being implemented in the UK to optimise the roll-out of these exciting new therapies.
format Online
Article
Text
id pubmed-7509731
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-75097312020-10-01 Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites Pillai, Manon Davies, Michelle M. Thistlethwaite, Fiona C. Ther Adv Vaccines Immunother Review Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once considered a niche area of academic research, ATMPs now represent one of the fastest-growing areas of clinical development. The field has seen a rapid expansion of academic and commercial entities successfully translating ATMP research into the clinic. This is reflected in projection that the global gene and cell therapy market will be worth US $11.96 billion by 2025. However, these treatments are complex to deliver and frequently do not fit naturally into established healthcare systems. In the United Kingdom (UK) there has been a long-standing interest in ATMP research and, in order to meet the ambition to act as an international hub of activity for delivery of ATMPs, a collaborative network of Advanced Therapy Treatment Centres (ATTCs) has been established. This review explores the challenges of delivery in the clinical setting, focussing on one form of ATMP, Adoptive Cell Therapy (ACT). We describe the strategy being implemented in the UK to optimise the roll-out of these exciting new therapies. SAGE Publications 2020-09-20 /pmc/articles/PMC7509731/ /pubmed/33015538 http://dx.doi.org/10.1177/2515135520944355 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Pillai, Manon
Davies, Michelle M.
Thistlethwaite, Fiona C.
Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title_full Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title_fullStr Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title_full_unstemmed Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title_short Delivery of adoptive cell therapy in the context of the health-care system in the UK: challenges for clinical sites
title_sort delivery of adoptive cell therapy in the context of the health-care system in the uk: challenges for clinical sites
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509731/
https://www.ncbi.nlm.nih.gov/pubmed/33015538
http://dx.doi.org/10.1177/2515135520944355
work_keys_str_mv AT pillaimanon deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites
AT daviesmichellem deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites
AT thistlethwaitefionac deliveryofadoptivecelltherapyinthecontextofthehealthcaresystemintheukchallengesforclinicalsites